Becton Dickinson Announces Planned Spinoff of Biosciences & Diagnostics — Waters Deal via $17.5 B Reverse Morris Trust

Becton, Dickinson and Company (BDX) is poised to spin off its Biosciences & Diagnostic Solutions business—then merge it with Waters Corporation(WAT) in a reverse Morris Trust transaction valuing the deal at approximately $17.5 billion (Becton, Dickinson and Company). 📊 Key Deal Metrics & Structure Metric Details 2025 Pro Forma Sales ~$6.5 B combined revenues 2025 Pro Forma Adjusted EBITDA ~$2.0 B…